Sandhu, Paul
Ong, Jann P.
Garg, Vinay
Altaha, Mustafa
Bello, Olubenga
Singal, Sewa R.
Verma, Subodh
Yan, Andrew T.
Connelly, Kim A. http://orcid.org/0000-0002-1031-3137
Funding for this research was provided by:
AstraZeneca Canada
Article History
Received: 1 October 2020
Accepted: 17 December 2020
First Online: 23 January 2021
Compliance with ethical standards
:
: Dr Connelly is listed as an inventor on a patent application by Boehringer Ingelheim on the use of dipeptidyl peptidase-4 inhibitors in heart failure; and reports receiving research grants to his institution from AstraZeneca, Servier, and Boehringer Ingelheim; support for travel to scientific meetings from Boehringer Ingelheim and honoraria for speaking engagements and ad hoc participation in advisory boards from Servier, Merck, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Ferring, Novo Nordisk, Novartis, and Janssen.
: The study was approved by St. Michael’s Hospital Research Ethics Board.
: All participants were consented to participate. Study team ensured that participants were made aware that participation or lack thereof will have no impact on clinical care provided.
: Data can be made available upon request.